πŸ‡ΊπŸ‡Έ FDA
Patent

US 9375402

Oral formulations of kinase inhibitors

granted A61KA61K31/435A61K31/5377

Quick answer

US patent 9375402 (Oral formulations of kinase inhibitors) held by VERASTEM, INC. expires Mon Jun 23 2036 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
VERASTEM, INC.
Grant date
Tue Jun 28 2016 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jun 23 2036 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
4
CPC classes
A61K, A61K31/435, A61K31/5377, A61K9/107, A61P